Improvement Effect of Soyeom Pharmacopuncture on Gout via NLRP3 Inflammasome Regulation
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: Gout is an inflammatory arthritis of the joints and soft tissues occurring due to deposition of monosodium urate (MSU) crystals, which are caused by persistent hyperuricemia. Soyeom pharmacopuncture is one treatment method that has been traditionally used for pain management in Oriental medicine. However, studies on its effect in reducing gout pain have been insufficient. Therefore, we selected Soyeom pharmacopuncture among natural products used in Korea as the new target of our study. Methods: The effects of Soyeom pharmacopuncture were examined in mouse models of acute gout induced by injection of MSU crystals into footpads. IL-1β, IL-6, and TNF-α production were examined by immunoblotting and enzyme-linked immunosorbent assay as hallmarks of NLRP3 inflammasome and cytokine activation. Results: Soyeom pharmacopuncture reduced foot edema in gout-induced mice, as well as IL-1β, nitrite, IL-6, and TNF-α production. Moreover, Soyeom pharmacopuncture also reduced MSU-induced gout inflammatory gene expressions, specifically those in the NF-kB pathway. Conclusion: Pharmacopuncture may serve as a new solution for other inflammatory diseases as well. Through active follow-up studies, we could thoroughly understand the clinical value of Soyeom pharmacopuncture.
Abstract
Objectives: Gout is an inflammatory arthritis of the joints and soft tissues occurring due to deposition of monosodium urate (MSU) crystals, which are caused by persistent hyperuricemia. Soyeom pharmacopuncture is one treatment method that has been traditionally used for pain management in Oriental medicine. However, studies on its effect in reducing gout pain have been insufficient. Therefore, we selected Soyeom pharmacopuncture among natural products used in Korea as the new target of our study. Methods: The effects of Soyeom pharmacopuncture were examined in mouse models of acute gout induced by injection of MSU crystals into footpads. IL-1β, IL-6, and TNF-α production were examined by immunoblotting and enzyme-linked immunosorbent assay as hallmarks of NLRP3 inflammasome and cytokine activation. Results: Soyeom pharmacopuncture reduced foot edema in gout-induced mice, as well as IL-1β, nitrite, IL-6, and TNF-α production. Moreover, Soyeom pharmacopuncture also reduced MSU-induced gout inflammatory gene expressions, specifically those in the NF-kB pathway. Conclusion: Pharmacopuncture may serve as a new solution for other inflammatory diseases as well. Through active follow-up studies, we could thoroughly understand the clinical value of Soyeom pharmacopuncture.
참고문헌 (23)
- Rider TG, "The modern management of gout", Rheumatology (Oxford), 49(1), pp.5~14 (2010)
- Dalbeth N, "Gout", Lancet, 397(10287), pp.1843~1855 (2021)
- Hochberg MC, "Racial differences in the incidence of gout. The role of hypertension", Arthritis Rheum, 38(5), pp.628~632 (1995)
- Choi HK, "Pathogenesis of gout", Ann Intern Med, 143(7), pp.499~516 (2005)
- Krishnan E, "Gout and the risk of acute myocardial infarction", Arthritis Rheum, 54(8), pp.2688~2696 (2006)
- Dalbeth N, "Gout", Nat Rev Dis Primers, 5(1), pp.69~ (2019)
- Kearney PM, "Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials", BMJ, 332(7553), pp.1302~1308 (2006)
- McKenzie BJ, "Colchicine for acute gout", Cochrane Database Syst Rev, 8(8), pp.CD006190~ (2021)
- Yook TH, "Clinical observation about the extent of improvement of low back pain patient through medi-acupuncture therapy", J Korean Orient Med Soc, 16(1), pp.184~197 (1995)
- So AK, "Inflammation in gout : mechanisms and therapeutic targets", Nat Rev Rheumatol, 13(11), pp.639~647 (2017)
- Yang G, "Suppression of NLRP3 inflammasome by oral treatment with sulforaphane alleviates acute gouty inflammation", Rheumatology (Oxford), 57(4), pp.727~736 (2018)
- Yang G, "Direct binding to NLRP3 pyrin domain as a novel strategy to prevent NLRP3-driven inflammation and gouty arthritis", Arthritis Rheumatol, 72(7), pp.1192~1202 (2020)
- Rees F, "Optimizing current treatment of gout", Nat Rev Rheumatol, 10(5), pp.271~283 (2014)
- Richette P, "Should prednisolone be first-line therapy for acute gout?", Lancet, 372(9646), pp.1301~ (2008)
- GroffGD, "Systemic steroid therapy for acute gout : a clinical trial and review of the literature", Semin Arthritis Rheum, 19(6), pp.329~336 (1990)
- 이광호, "History of Research on Pharmacopuncture in Korea", Journal of Pharmacopuncture, 19(2), pp.101~108 (2016), 대한약침학회[DOI]
- Bang M, "Pharmacopuncture for asthma : a systematic review and a meta-analysis of randomized controlled trials", Eur J Integr Med, 11, pp.6~17 (2017)
- Wang JQ, "Inhibitory effect of Zanthoxylum bungeanum seed oil on ovalbumin‑induced lung inflammation in a murine model of asthma", Mol Med Rep, 13(5), pp.4289~4302 (2016)
- Kelley N, "The NLRP3 inflammasome : an overview of mechanisms of activation and regulation", Int J Mol Sci, 20(13), pp.3328~ (2019)
- Schroder K, "The inflammasomes", Cell, 140(6), pp.821~832 (2010)
- Martinon F, "Gout : new insights into an old disease", J Clin Invest, 116(8), pp.2073~2075 (2006)
- Özenver N, "Phytochemical inhibitors of the NLRP3inflammasome for the treatment of inflammatory diseases", Pharmacol Res, 170, pp.105710~ (2021)
- Wortmann M, "Inflammasome targeted therapy as novel treatment option for aortic aneurysms and dissections : a systematic review of the preclinical evidence", Front Cardiovasc Med, 8, pp.805150~ (2022)